More than 5,000 potential treatments for rare diseases are currently languishing on pharmaceutical company shelves, representing a vast, untapped reservoir…
Read More
Novo Nordisk Secures European Approval for Oral Wegovy, Bolstering First-Mover Advantage in Obesity Pill Market
Novo Nordisk has solidified its pioneering position in the burgeoning market for oral obesity medications with the European Commission’s marketing…
Read More
UK Recommends Routine Meningitis B Vaccination for Adolescents Following Data Review
The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has put forth a significant recommendation for the introduction of a…
Read More
CNPV: A gamechanger for the pharma industry or simply more chaos?
The pharmaceutical industry finds itself at a pivotal juncture with the advent of the U.S. Food and Drug Administration’s (FDA)…
Read More
MSD Secures Landmark Approval for First Oral PCSK9 Inhibitor, Ushering in New Era for Cholesterol Management and Strategic Diversification
The pharmaceutical landscape has been significantly reshaped with MSD (Merck & Co.) achieving a monumental victory: the US Food and…
Read More
Novartis Fabhalta Receives Traditional FDA Approval for IgAN Treatment
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Novartis for Fabhalta (iptacopan), a groundbreaking oral Factor…
Read More
Kerendia Recommended for Broader Heart Failure Treatment in England, Offering New Hope for Patients with Preserved Ejection Fraction
England’s National Health Service (NHS) is set to expand its treatment options for chronic heart failure (CHF) with the National…
Read More
UK and Switzerland Forge Landmark Free Trade Agreement, Cementing Pharmaceutical Intellectual Property Protections
The United Kingdom and Switzerland have finalized a groundbreaking free trade agreement that explicitly enshrines intellectual property (IP) protections for…
Read More
J&J raises FY26 outlook following positive Q2 – Pharmaceutical Technology
Johnson & Johnson (J&J) announced robust second-quarter (Q2) revenues totaling approximately $25.3 billion, marking a significant 6.6% increase year-over-year (YoY).…
Read More
How CTF is trying to rescue pharma’s shelved rare disease drugs
More than 5,000 potential treatments for rare diseases are currently languishing on pharmaceutical company shelves, representing a vast, untapped reservoir…
Read More
